TY - JOUR
T1 - Thrombolysis in stroke patients with elevated inflammatory markers
AU - Altersberger, Valerian L.
AU - Enz, Lukas S.
AU - Sibolt, Gerli
AU - Hametner, Christian
AU - Nannoni, Stefania
AU - Heldner, Mirjam R.
AU - Stolp, Jeffrey
AU - Jovanovic, Dejana R.
AU - Zini, Andrea
AU - Pezzini, Alessandro
AU - Wegener, Susanne
AU - Cereda, Carlo W.
AU - Ntaios, George
AU - Thrombolysis in Stroke Patients (TRISP) collaborators
AU - Räty, Silja
AU - Gumbinger, Christoph
AU - Heyse, Miriam
AU - Polymeris, Alexandros A.
AU - Zietz, Annaelle
AU - Schaufelbuehl, Anna
AU - Strambo, Davide
AU - Padlina, Giovanna
AU - Slavova, Nedelina
AU - Tiainen, Marjaana
AU - Valkonen, Kati
AU - Velzen, Twan J. van
AU - Bigliardi, Guido
AU - Stanarcevic, Predrag
AU - Magoni, Mauro
AU - Luft, Andreas
AU - Bejot, Yannick
AU - Vandelli, Laura
AU - Padjen, Visnja
AU - Nederkoorn, Paul J.
AU - Arnold, Marcel
AU - Michel, Patrik
AU - Ringleb, Peter A.
AU - Curtze, Sami
AU - Engelter, Stefan T.
AU - Gensicke, Henrik
N1 - Funding Information:
V.L. Altersberger, G. Sibolt, A. Zietz, A. Schaufelbühl, A. Polymeris, C. Hametner, M. Heyse, G. Bigliardi, J. Stolp, T.J. van Velzen, G. Padlina, N. Slavova, M. Tiainen, K. Valkonen, L. Vandelli, M. Magoni, A. Luft, A. Pezzini, S. Nannoni, S. Räty, and S. Curtze report no disclosures. Lukas S Enz has received funding from the Swiss National Science Foundation (323530_171139). M.R. Heldner reports Scientific Advisory honoraria by Amgen and a grant from the Bangerter foundation, outside the submitted work. A. Zini has received funding for speaker honoraria and consulting fees from Boehringer-Ingelheim and Medtronic, speaker honoraria from Cerenovus, for scientific advisory board from Boehringer-Ingelheim and Stryker. V. Padjen travel or speaker honoraria from Boehringer Ingelheim and Pfizer; honoraria from scientific advisory board from Medtronic. C. Gumbinger is the head of the commission telestroke service of the German Stroke Society (DSG). D. Strambo has received congress travel support from Bristol-Myers Squibb, and research grant from the Swiss Heart Foundation and from the University of Lausanne. All fees are paid to his institution. C.W. Cereda has received modest honoraria for scientific advisory board from Bayer, Boehringer-Ingelheim and iSchemaview; Research grants from the Swiss Heart Foundation. Susanne Wegener received research funds by the Swiss National Science Foundation, the UZH Clinical research priority program (CRPP) stroke, the Swiss Heart foundation, Boehringer- Ingelheim, a speaker honorarium from Amgen and a consultancy fee from Bayer. Y. Béjot reports personal fees from AstraZeneca, BMS, Pfizer, Medtronic, MSD France, Amgen, Servier, and Boehringer-Ingelheim, outside the submitted work. D.R. Jovanović has received for travel or speaker honoraria from Bayer, Boehringer Ingelheim, Pfizer, Sanofi and Medtronic. She has served on scientific advisory board for Boehringer Ingelheim. P. Stanarcevic has received travel or speaker honoraria from Boehringer Ingelheim, Pfizer and Sandoz; also, honoraria from scientific advisory board from Medtronic and Boehringer Ingelheim. P. Michel has received has received through his institution research grants from the Swiss National Science Foundation, the Swiss Heart Foundation and the ERISTA program (Pfizer/BMS); and consulting fees from Medtronic. All this support is goes to his institution and is used for stroke education and research. P.A. Ringleb has received modest honoraria for lectures and advisory board from Boehringer-Ingelheim. The University Hospital Heidelberg is sponsor of the ECASS4-trial, examining the role of rtPA in an extended time-window, which is financed by Boehringer-Ingelheim. M. Arnold received Speaker honoraria from Bayer, Boehringer Ingelheim, and Covidien; Scientific advisory board honoraria from Amgen, Bayer, Boehringer Ingelheim, BMS, Pfizer, Covidien, Daichy Sankyo and Nestlé Health Science. Research grants from the Swiss Heart Foundation and the Swiss National Science Foundation. P.J. Nederkoorn has received funding from the Dutch heart foundation for acute stroke intervention trials in the Collaboration for New Trials in Stroke (CONTRAST) consortium. S.T. Engelter has received funding for travel or speaker honoraria from Bayer Boehringer-Ingelheim, and Daiichi-Sankyo. He has served on scientific advisory boards for Bayer, Boehringer-Ingelheim, BMS/Pfizer, MindMaze and on the editorial board of Stroke. He has received an educational grant from Pfizer and research support from the Science Funds (Wissenschaftsfonds) of the University Hospital Basel, the University Basel, the Swiss Heart Foundation and the Swiss National Science Foundation. H. Gensicke has received research support from the Swiss National Science Foundation, advisory board honoraria from Daiichi Sankyo and funding for travel from BMS/Pfizer.
Publisher Copyright:
© 2022, The Author(s).
PY - 2022/10
Y1 - 2022/10
N2 - Objective: To investigate the prognostic value of white blood cell count (WBC) on functional outcome, mortality and bleeding risk in stroke patients treated with intravenous thrombolysis (IVT). Methods: In this prospective multicenter study from the TRISP registry, we assessed the association between WBC on admission and 3-month poor outcome (modified Rankin Scale 3–6), mortality and occurrence of symptomatic intracranial hemorrhage (sICH; ECASS-II-criteria) in IVT-treated stroke patients. WBC was used as continuous and categorical variable distinguishing leukocytosis (WBC > 10 × 109/l) and leukopenia (WBC < 4 × 109/l). We calculated unadjusted/ adjusted odds ratios with 95% confidence intervals (OR [95% CI]) with logistic regression models. In a subgroup, we analyzed the association of combined leukocytosis and elevated C-reactive protein (CRP > 10 mg/l) on outcomes. Results: Of 10,813 IVT-treated patients, 2527 had leukocytosis, 112 leukopenia and 8174 normal WBC. Increasing WBC (by 1 × 109/l) predicted poor outcome (ORadjusted 1.04[1.02–1.06]) but not mortality and sICH. Leukocytosis was independently associated with poor outcome (ORadjusted 1.48[1.29–1.69]) and mortality (ORadjusted 1.60[1.35–1.89]) but not with sICH (ORadjusted 1.17[0.94–1.45]). Leukopenia did not predict any outcome. In a subgroup, combined leukocytosis and elevated CRP had the strongest association with poor outcome (ORadjusted 2.26[1.76–2.91]) and mortality (ORadjusted 2.43[1.86–3.16]) when compared to combined normal WBC and CRP. Conclusion: In IVT-treated patients, leukocytosis independently predicted poor functional outcome and death. Bleeding complications after IVT were not independently associated with leukocytosis.
AB - Objective: To investigate the prognostic value of white blood cell count (WBC) on functional outcome, mortality and bleeding risk in stroke patients treated with intravenous thrombolysis (IVT). Methods: In this prospective multicenter study from the TRISP registry, we assessed the association between WBC on admission and 3-month poor outcome (modified Rankin Scale 3–6), mortality and occurrence of symptomatic intracranial hemorrhage (sICH; ECASS-II-criteria) in IVT-treated stroke patients. WBC was used as continuous and categorical variable distinguishing leukocytosis (WBC > 10 × 109/l) and leukopenia (WBC < 4 × 109/l). We calculated unadjusted/ adjusted odds ratios with 95% confidence intervals (OR [95% CI]) with logistic regression models. In a subgroup, we analyzed the association of combined leukocytosis and elevated C-reactive protein (CRP > 10 mg/l) on outcomes. Results: Of 10,813 IVT-treated patients, 2527 had leukocytosis, 112 leukopenia and 8174 normal WBC. Increasing WBC (by 1 × 109/l) predicted poor outcome (ORadjusted 1.04[1.02–1.06]) but not mortality and sICH. Leukocytosis was independently associated with poor outcome (ORadjusted 1.48[1.29–1.69]) and mortality (ORadjusted 1.60[1.35–1.89]) but not with sICH (ORadjusted 1.17[0.94–1.45]). Leukopenia did not predict any outcome. In a subgroup, combined leukocytosis and elevated CRP had the strongest association with poor outcome (ORadjusted 2.26[1.76–2.91]) and mortality (ORadjusted 2.43[1.86–3.16]) when compared to combined normal WBC and CRP. Conclusion: In IVT-treated patients, leukocytosis independently predicted poor functional outcome and death. Bleeding complications after IVT were not independently associated with leukocytosis.
KW - CRP
KW - Inflammation
KW - Stroke
KW - Thrombolysis
KW - White blood cell count
UR - https://www.scopus.com/pages/publications/85130775854
U2 - 10.1007/s00415-022-11173-0
DO - 10.1007/s00415-022-11173-0
M3 - Article
C2 - 35622132
SN - 0340-5354
VL - 269
SP - 5405
EP - 5419
JO - Journal of neurology
JF - Journal of neurology
IS - 10
ER -